Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

American Shared Hospital Services Q3 2026 Results: Net Loss of $620K, Loss Widens

American Shared Hospital Services reported a net loss of $2,866,000 for the nine months ended September 30, 2026, compared to a loss of $1,719,000 in the prior year period. While total revenues increased to $23,138,000, higher operating costs and selling and administrative expenses led to an increased operating loss of $2,598,000.

Watch the American Shared Hospital Services earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue7.67.2
Gross profit1.51.6
Profit before tax-0.7-0.3
Net income-0.6-0.0
EPS (diluted, $ a share)$-0.09$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+6.3%
Gross margin19.9%
Operating margin-10.0%
Source

10-Q filed with the SEC, NYSE: AMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

American Shared Hospital Services: key numbers

Share price
$1.03Close, Nov 17
Market cap
$6.88M
Shares outstanding
6.67MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from American Shared Hospital Services

All →
11:28 AM ET 8-K
Financial Results

American Shared Hospital Services Financial Results

American Shared Hospital Services reported Q3 2026 revenue of $7.6 million, a 6% increase year-over-year, driven by a 14% rise in Direct Patient Services revenue. The company generated $5.8 million in operating cash flow during the first nine months of 2026 and increased its cash position to approximately $9.5 million.

“During the third quarter, we continued to make progress in growing our Direct Patient Services business, with revenue in this segment increasing 14% year over year. For the first nine months of 2026, total revenue increased 14%, driven by continued growth in our Rhode Island radiation therapy operations and higher procedure volumes at our international Gamma Knife facilities.”

Craig Tagawa, Interim Chief Executive Officer

“We continue to focus on positioning the Company for long-term success by building on our established presence in radiation oncology and pursuing opportunities to expand the reach and capabilities of our technology and services.”

Ray Stachowiak, Executive Chairman

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.